Veterinary Lab Automation Global Market Report 2023 Now Available, Covers Asia-Pacific, North America, Europe, and More

The veterinary lab automation market is experiencing robust growth, expanding from $1.26 billion in 2025 to $1.36 billion in 2026 at an 8.4% CAGR, with projections to reach $1.9 billion by 2030. Growth is driven by rising demand for rapid diagnostics, AI integration, companion animal care expansion, and robotic workflow adoption. North America leads the market while Asia-Pacific is positioned for rapid expansion.

07/13/2026, 7:32 AM • GlobeNewswire

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty

AbbVie, a Dividend King, is acquiring Apogee Therapeutics for $10.9 billion to strengthen its drug pipeline and maintain its dividend growth streak. The deal brings late-stage drug candidates like zumilokibart for atopic dermatitis and respiratory drugs, helping AbbVie replace revenue lost from Humira's patent expiration with newer products like Skyrizi and Rinvoq.

07/11/2026, 8:15 PM • The Motley Fool

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories and Glaukos represent two contrasting healthcare investment strategies: Abbott offers stability through diversification, strong profitability, and recent acquisitions like Exact Sciences, while Glaukos provides high-growth potential in specialized ophthalmic treatments with innovative products like iDose and Epioxa. Abbott trades at a lower valuation multiple but faces integration challenges and legal risks, while Glaukos shows rapid 32% revenue growth but remains unprofitable and dependent on a single manufacturing location.

07/08/2026, 5:03 PM • The Motley Fool

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

While Eli Lilly and Novo Nordisk are leaders in the GLP-1 market, Becton, Dickinson and Abbott Laboratories offer better indirect exposure to the GLP-1 boom. Becton, Dickinson supplies prefillable syringes with soaring demand and is a Dividend King, while Abbott's continuous glucose monitoring devices see increased adoption alongside GLP-1 medicines.

07/07/2026, 5:30 PM • The Motley Fool

3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio

The article recommends three healthcare stocks for long-term buy-and-hold portfolios: Johnson & Johnson, Abbott Laboratories, and UnitedHealth Group. All three are praised for their stable dividends, strong cash flows, economic moats, and ability to weather economic downturns. Johnson & Johnson and Abbott are Dividend Kings with 64 and 54 consecutive years of dividend increases respectively, while UnitedHealth Group benefits from its dual-engine model combining insurance and healthcare delivery.

07/06/2026, 8:30 AM • The Motley Fool

Brain Implants Market Size to Reach USD 18.39 Billion by 2035, Growing at 9.99% CAGR | SNS Insider

The global brain implants market, valued at USD 7.10 billion in 2025, is projected to reach USD 18.39 billion by 2035, growing at a CAGR of 9.99%. Growth is driven by rising prevalence of neurological disorders and increasing adoption of deep brain stimulation, neuromodulation systems, and brain-computer interfaces. North America leads the market, with the U.S. expected to grow from USD 3.16 billion to USD 8.17 billion by 2035.

06/27/2026, 4:30 AM • GlobeNewswire

Bloodstream Infection Testing Market Size to Reach USD 1,404.68 Million by 2035 | SNS Insider

The global bloodstream infection testing market is expected to grow at a CAGR of 4.80% through 2035, driven by rising sepsis cases, antimicrobial stewardship mandates, and adoption of rapid molecular diagnostics. North America leads the market, with the U.S. contributing 87.4% of regional revenues, while Asia Pacific shows the fastest growth. Key technologies include molecular diagnostics and whole blood testing, which are rapidly replacing traditional blood culture methods.

06/26/2026, 4:30 AM • GlobeNewswire

3 Monster Stocks to Hold for the Next 10 Years

The article recommends three healthcare stocks as long-term investments: Eli Lilly, benefiting from the high-growth weight loss drug market; AbbVie, successfully transitioning from Humira patent expiration with new immunology drugs; and Abbott Laboratories, offering diversification across medical devices, diagnostics, nutrition, and pharmaceuticals. These established companies are positioned for sustained growth over the next decade.

06/23/2026, 6:05 AM • The Motley Fool

Enteric Disease Testing Market Worth USD 5.86 Billion by 2035 | SNS Insider

The global Enteric Disease Testing Market is valued at USD 4.08 billion in 2025 and is projected to reach USD 5.86 billion by 2035, growing at a CAGR of 3.70%. Growth is driven by increasing foodborne and waterborne disease prevalence, rising demand for rapid pathogen detection, and expanding adoption of multiplex molecular diagnostics. North America and Europe are leading markets, with Asia-Pacific emerging as the fastest-growing region.

06/23/2026, 4:35 AM • GlobeNewswire

5 Dividend Stocks to Buy and Hold Forever

The article highlights five blue-chip dividend stocks suitable for long-term buy-and-hold investing: AbbVie, McDonald's, Johnson & Johnson, Walmart, and Becton Dickinson. These companies have demonstrated decades of consecutive dividend increases and strong financial fundamentals, with dividends well-covered by earnings and solid growth prospects ahead.

06/22/2026, 6:15 AM • The Motley Fool

Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider

The global ovarian cancer diagnostics market is valued at USD 4.92 billion in 2025 and is projected to reach USD 8.08 billion by 2035, growing at a CAGR of 5.06%. Growth is driven by rising ovarian cancer incidence, increasing adoption of AI-powered imaging, biomarker testing, and precision oncology diagnostics. North America leads with 41.2% market share, while imaging and hospital laboratories dominate their respective segments.

06/19/2026, 5:39 AM • GlobeNewswire

The Hormuz Reopening Trade: These 20 Large-Cap Stocks Still Haven't Caught Up To Pre-War Levels

Following President Trump's announcement of a U.S.-Iran peace deal and the reopening of the Strait of Hormuz, oil prices plunged 5.4% to $80/barrel. However, 20 large-cap stocks worth over $100 billion remain trading 15-24% below their pre-war levels from February 27, 2026. The laggards span consumer staples, healthcare, software, and mining sectors, with weakness extending beyond the war premium as these companies face ongoing margin pressures from higher energy costs.

06/15/2026, 11:29 AM • Benzinga

Over 100 Organizations Thank America’s Blood Donors on World Blood Donor Day

More than 100 prominent organizations have united to promote World Blood Donor Day on June 14, 2026, and Blood Advocacy Week (June 8-12). The initiative highlights that while blood transfusions are needed every 2 seconds in America, less than 3% of eligible Americans donate blood. The campaign theme is 'One Drop of Humanity. Give Blood. Save Lives.' emphasizing the critical need for volunteer blood donors.

06/14/2026, 8:54 AM • GlobeNewswire

Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months

Boston Scientific shares have plummeted over 50% year-to-date due to repeated downward guidance revisions, particularly regarding declining Watchman procedure usage. Despite bearish market sentiment, 27 of 31 analysts maintain buy ratings with a consensus price target of $78 (65% upside), though the article cautions this recovery may be challenging without faster-than-expected growth acceleration.

06/13/2026, 12:15 AM • The Motley Fool

Abbott declares 410th consecutive quarterly dividend

Abbott Laboratories announced its 410th consecutive quarterly dividend of 63 cents per share, payable on August 17, 2026. The company has increased its dividend for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index.

06/12/2026, 2:29 PM • Benzinga